Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.87)
# 1,581
Out of 4,832 analysts
80
Total ratings
45.76%
Success rate
7.38%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $22 | $17.20 | +27.91% | 16 | Feb 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $10.76 | +39.41% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $4.49 | +78.17% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $14.02 | +256.63% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $116.87 | +16.37% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $3.90 | +310.26% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $7.59 | +716.86% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.11 | +981.08% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $6.61 | +217.70% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $36.20 | +201.10% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.05 | +661.90% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.41 | +609.22% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $0.30 | +1,594.92% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $4.03 | +48.88% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.76 | +660.87% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $65.71 | -65.00% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $20.52 | +75.44% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 11, 2025
Initiates: Hold
Price Target: $22
Current: $17.20
Upside: +27.91%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $10.76
Upside: +39.41%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $4.49
Upside: +78.17%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $14.02
Upside: +256.63%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $116.87
Upside: +16.37%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $3.90
Upside: +310.26%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $7.59
Upside: +716.86%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.11
Upside: +981.08%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $6.61
Upside: +217.70%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $36.20
Upside: +201.10%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.05
Upside: +661.90%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $1.41
Upside: +609.22%
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $0.30
Upside: +1,594.92%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $4.03
Upside: +48.88%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $2.76
Upside: +660.87%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $65.71
Upside: -65.00%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $20.52
Upside: +75.44%